Submucosal Bevacizumab

( DrugBank: - / KEGG DRUG: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
227	Osler disease	3

227. Osler disease

Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01314274 (ClinicalTrials.gov)	March 2011	9/3/2011	Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumabin Hereditary ...	HHT;Morbus Osler;Epistaxis	Drug: Bevacizumab;Drug: NaCl	Medical University of Vienna	NULL	Completed	18 Years	80 Years	Both	15	Phase 2	Austria
2	EUCTR2009-018049-19-AT (EUCTR)	13/12/2010	23/11/2010	A randomized double blind placebo controlled trial of intranasal submucosal bevacizumabin hereditary ...	A randomized double blind placebo controlled trial of intranasal submucosal bevacizumabin hereditary ...	epistaxis	Trade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung INN or Proposed INN: ...	Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten	NULL	Not Recruiting			Female: yes Male: yes	30		Austria
3	NCT01402531 (ClinicalTrials.gov)	July 22, 2010	19/7/2011	Submucosal Bevacizumabfor the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrha ...	Submucosal Bevacizumabfor the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrha ...	Hereditary Hemorrhagic Telangiectasia (HHT)	Drug: Submucosal Bevacizumab	University of California, San Diego	NULL	Completed	18 Years	N/A	All	10	Phase 2	United States

First Previous1Next Last